Syndax Q2 net loss $44.6M; axatilimab ORR up to 74% in cGVHD; two filings on track for 2023

Syndax Pharmaceuticals Inc

2023-Q2 EPS reported -$1.23

Axatilimab AGAVE-201: ORR 74% at 0.3 mg/kg Q2W; all three cohorts met primary endpoint in cGVHD.
Revumenib AUGMENT-101 topline data from KMT2Ar cohorts expected Q3 2023; NDA filing by year-end.
Q2 2023 net loss $44.6M ($0.64/sh) vs $37.6M ($0.62/sh) in Q2 2022.
Cash and investments $418.3M; 69.7M shares outstanding.
FY 2023 R&D guidance $160-175M; total operating expenses $225-240M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Syndax Pharmaceuticals Inc reported the quarter ended June 30, 2023 results: net income net loss attributable to common stockholders of $44.6 million, or $0.64 per share, EPS $0.64 per share. Guidance reaffirmed.

Period: the quarter ended June 30, 2023
Net income: net loss attributable to common stockholders of $44.6 million, or $0.64 per share
EPS: $0.64 per share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

For the three months ended June 30, 2023, Syndax reported a net loss attributable to common stockholders of $44.6 million, or $0.64 per share, compared to a net loss attributable to common stockholders of $37.6 million, or $0.62 per share, for the comparable prior year period.

View on SEC.gov

Browse all earnings releases →

Syndax Pharmaceuticals Inc filing history →

Source: SEC EDGAR

accession 0000950170-23-037936

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.